Publications by authors named "John Aspegren"

Claim this Profile
S
Safety and tolerability of long-term treatment with darolutamide in patients with metastatic castration-resistant prostate cancer.
Robert Hugh Jones, Karim Fizazi, Nicholas D James, Teuvo L Tammela, Nobuaki Matsubara, John Aspegren

Prostate Cancer Prostatic Dis· December 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pregabalin Alleviates Anxiety and Fear in Cats during Transportation and Veterinary Visits-A Clinical Field Study.
Terttu Lamminen, Mira Korpivaara, John Aspegrén, Clara Palestrini, Karen L Overall

Animals (Basel)· January 2023

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
N
Nanoparticle-based oral formulation can surprise you with inferior in vivo absorption in humans.
Mayank Singhal, Elina Turunen, Tuula Ahtola-Sätilä, John Aspegren, J Raymond Bratty

Eur J Pharm Biopharm· August 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Tasipimidine-the pharmacological profile of a novel orally active selective α-adrenoceptor agonist.
Jyrki Lehtimäki, Niina Jalava, Kaisa Unkila, John Aspegren, Antti Haapalinna

Eur J Pharmacol· May 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexmedetomidine oromucosal gel reduces fear and anxiety in dogs during veterinary visits: A randomised, double-blind, placebo-controlled clinical pilot study.
Mira Korpivaara, Mirja Huhtinen, John Aspegrén, Karen Overall

Vet Rec· December 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy of a Single Dose of Pregabalin on Signs of Anxiety in Cats During Transportation-A Pilot Study.
Terttu Lamminen, Mira Korpivaara, Minna Suokko, John Aspegrén, Clara Palestrini

Front Vet Sci· September 2021

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
F
First-in-human Phase 1 open label study of the BET inhibitor ODM-207 in patients with selected solid tumours.
Malaka Ameratunga, Irene Braña, Petri Bono, Sophie Postel-Vinay, Ruth Plummer, John Aspegren

Br J Cancer· December 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Detomidine Oromucosal Gel for Alleviation of Acute Anxiety and Fear in Horses: A Pilot Study.
Francesca Dai, Julia Rausk, John Aspegren, Mirja Huhtinen, Simona Cannas

Front Vet Sci· October 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Chemotherapy-naïve and CYP17 Inhibitor-naïve Patients: Follow-up from the ARADES and ARAFOR Trials.
Neal D Shore, Teuvo L Tammela, Christophe Massard, Petri Bono, John Aspegren

Eur Urol Focus· July 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and Antitumour Activity of ODM-201 (BAY-1841788) in Castration-resistant, CYP17 Inhibitor-naïve Prostate Cancer: Results from Extended Follow-up of the ARADES Trial.
Karim Fizazi, Christophe Massard, Petri Bono, Vesa Kataja, Nicholas James, John Aspegren

Eur Urol Focus· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
B
Bone Scan Index and Progression-free Survival Data for Progressive Metastatic Castration-resistant Prostate Cancer Patients Who Received ODM-201 in the ARADES Multicentre Study.
Mariana Reza, Robert Jones, John Aspegren, Christophe Massard, Leena Mattila

Eur Urol Focus· December 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Activity and safety of ODM-201 in patients with progressive metastatic castration-resistant prostate cancer (ARADES): an open-label phase 1 dose-escalation and randomised phase 2 dose expansion trial.
Karim Fizazi, Christophe Massard, Petri Bono, Robert Jones, Vesa Kataja, John Aspegren

Lancet Oncol· August 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical evaluation of the efficacy and safety of a constant rate infusion of dexmedetomidine for postoperative pain management in dogs.
Chiara Valtolina, Joris H Robben, Joost Uilenreef, Joanna C Murrell, John Aspegrén

Vet Anaesth Analg· July 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dexmedetomidine constant rate infusion for 24 hours during and after propofol or isoflurane anaesthesia in dogs.
Guan-Yu Lin, Joris H Robben, Joanna C Murrell, John Aspegrén, Brett C McKusick

Vet Anaesth Analg· March 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of the clinical efficacy and safety of dexmedetomidine or medetomidine in cats and their reversal with atipamezole.
Mikael Granholm, Brett C McKusick, Fia C Westerholm, John C Aspegrén

Vet Anaesth Analg· July 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis